No OS Benefit From PROSTVAC-V/F in mCRPC

OS with the PSA-targeted, poxvirus-based cancer vaccine was no better than placebo, and increased survival was attributed to better standard of care.

Source: CancerNetwork - June 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news